Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIP1601 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)
NCT04325620Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esomeprazole in gastroesophageal reflux disease (GERD), sponsored by Hanmi Pharmaceutical. Started Jun 2019; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04325620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325620.